Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Effects of Human Immunodeficiency Virus Type 1 (HIV-1) Antigen-Expanded Specific T-Cell Therapy and Vorinostat on Persistent HIV-1 Infection in People With HIV on Antiretroviral Therapy.
Gay CL, Hanley PJ, Falcinelli SD, Kuruc JD, Pedersen SM, Kirchherr J, Raines SLM, Motta CM, Lazarski C, Chansky P, Tanna J, Shibli A, Datar A, McCann CD, Sili U, Ke R, Eron JJ, Archin N, Goonetilleke N, Bollard CM, Margolis DM. Gay CL, et al. Among authors: lazarski c. J Infect Dis. 2024 Mar 14;229(3):743-752. doi: 10.1093/infdis/jiad423. J Infect Dis. 2024. PMID: 38349333
T-cell receptor sequencing demonstrates persistence of virus-specific T cells after antiviral immunotherapy.
Keller MD, Darko S, Lang H, Ransier A, Lazarski CA, Wang Y, Hanley PJ, Davila BJ, Heimall JR, Ambinder RF, Barrett AJ, Rooney CM, Heslop HE, Douek DC, Bollard CM. Keller MD, et al. Among authors: lazarski ca. Br J Haematol. 2019 Oct;187(2):206-218. doi: 10.1111/bjh.16053. Epub 2019 Jun 20. Br J Haematol. 2019. PMID: 31219185 Free PMC article. Clinical Trial.
SARS-CoV-2-specific T cells are rapidly expanded for therapeutic use and target conserved regions of the membrane protein.
Keller MD, Harris KM, Jensen-Wachspress MA, Kankate VV, Lang H, Lazarski CA, Durkee-Shock J, Lee PH, Chaudhry K, Webber K, Datar A, Terpilowski M, Reynolds EK, Stevenson EM, Val S, Shancer Z, Zhang N, Ulrey R, Ekanem U, Stanojevic M, Geiger A, Liang H, Hoq F, Abraham AA, Hanley PJ, Cruz CR, Ferrer K, Dropulic L, Gangler K, Burbelo PD, Jones RB, Cohen JI, Bollard CM. Keller MD, et al. Among authors: lazarski ca. Blood. 2020 Dec 17;136(25):2905-2917. doi: 10.1182/blood.2020008488. Blood. 2020. PMID: 33331927 Free PMC article.
Robust Antibody and T Cell Responses to SARS-CoV-2 in Patients with Antibody Deficiency.
Kinoshita H, Durkee-Shock J, Jensen-Wachspress M, Kankate VV, Lang H, Lazarski CA, Keswani A, Webber KC, Montgomery-Recht K, Walkiewicz M, Notarangelo LD, Burbelo PD, Fuss I, Cohen JI, Bollard CM, Keller MD. Kinoshita H, et al. Among authors: lazarski ca. J Clin Immunol. 2021 Aug;41(6):1146-1153. doi: 10.1007/s10875-021-01046-y. Epub 2021 May 13. J Clin Immunol. 2021. PMID: 33983545 Free PMC article.
Tumor-associated antigen-specific T cells with nivolumab are safe and persist in vivo in relapsed/refractory Hodgkin lymphoma.
Dave H, Terpilowski M, Mai M, Toner K, Grant M, Stanojevic M, Lazarski C, Shibli A, Bien SA, Maglo P, Hoq F, Schore R, Glenn M, Hu B, Hanley PJ, Ambinder R, Bollard CM. Dave H, et al. Among authors: lazarski c. Blood Adv. 2022 Jan 25;6(2):473-485. doi: 10.1182/bloodadvances.2021005343. Blood Adv. 2022. PMID: 34495306 Free PMC article. Clinical Trial.
SARS-CoV-2-Specific T Cell Responses Are Stronger in Children With Multisystem Inflammatory Syndrome Compared to Children With Uncomplicated SARS-CoV-2 Infection.
Conway SR, Lazarski CA, Field NE, Jensen-Wachspress M, Lang H, Kankate V, Durkee-Shock J, Kinoshita H, Suslovic W, Webber K, Smith K, Cohen JI, Burbelo PD, Zhang A, Teach SJ, Ibeh T, Delaney M, DeBiasi RL, Keller MD, Bollard CM. Conway SR, et al. Front Immunol. 2022 Jan 18;12:793197. doi: 10.3389/fimmu.2021.793197. eCollection 2021. Front Immunol. 2022. PMID: 35116027 Free PMC article.
42 results